AGER and endothelial dysfunction: With the present study we sought to test whether treatment of diabetic animals with the SGLT2i empagliflozin improves endothelial dysfunction, oxidative stress, AGE/RAGE signaling and inflammation in a well-characterized rat model of type 1 diabetes mellitus [3].